Modulatory effects of curcumin and green tea extract against experimentally induced pulmonary fibrosis: a comparison with N-acetyl cysteine.
J Biochem Mol Toxicol. 2012.
PMID: 23132788
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 1964 | 1 |
| 1965 | 1 |
| 1973 | 2 |
| 1976 | 1 |
| 1977 | 1 |
| 1979 | 2 |
| 1980 | 1 |
| 1982 | 2 |
| 1984 | 1 |
| 1985 | 1 |
| 1987 | 1 |
| 1988 | 3 |
| 1989 | 2 |
| 1990 | 2 |
| 1991 | 6 |
| 1993 | 1 |
| 1994 | 4 |
| 1995 | 3 |
| 1996 | 4 |
| 1997 | 4 |
| 1998 | 3 |
| 1999 | 2 |
| 2000 | 2 |
| 2001 | 1 |
| 2002 | 6 |
| 2003 | 5 |
| 2004 | 3 |
| 2005 | 9 |
| 2006 | 12 |
| 2007 | 6 |
| 2008 | 5 |
| 2009 | 11 |
| 2010 | 11 |
| 2011 | 15 |
| 2012 | 23 |
| 2013 | 27 |
| 2014 | 18 |
| 2015 | 32 |
| 2016 | 23 |
| 2017 | 17 |
| 2018 | 10 |
| 2019 | 20 |
| 2020 | 14 |
| 2021 | 13 |
| 2022 | 21 |
| 2023 | 15 |
| 2024 | 6 |
Search Results
352 results
Results by year
Citations
3
articles
found by citation matching
Thiol-redox antioxidants protect against lung vascular endothelial cytoskeletal alterations caused by pulmonary fibrosis inducer, bleomycin: comparison between classical thiol-protectant, N-acetyl-L-cysteine, and novel thiol antioxidant, N,N'-bis-2-mercaptoethyl isophthalamide.
Toxicol Mech Methods. 2012.
PMID: 22409285
Free PMC article.
Search results
Page 1
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
N Engl J Med. 2012 May 24;366(21):1968-77. doi: 10.1056/NEJMoa1113354. Epub 2012 May 20.
N Engl J Med. 2012.
PMID: 22607134
Free PMC article.
Clinical Trial.
BACKGROUND: A combination of prednisone, azathioprine, and N-acetylcysteine (NAC) has been widely used as a treatment for idiopathic pulmonary fibrosis. ...CONCLUSIONS: Increased risks of death and hospitalization were observed in patients with idiopathic …
BACKGROUND: A combination of prednisone, azathioprine, and N-acetylcysteine (NAC) has been widely used as a treatment for idiopathic …
Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review.
Drug Saf. 2021 Mar;44(3):273-290. doi: 10.1007/s40264-020-01026-y. Epub 2020 Dec 16.
Drug Saf. 2021.
PMID: 33326056
Free PMC article.
Review.
N-Acetylcysteine (NAC) is widely used in respiratory medicine, with a maximum licensed dose in chronic use of 600 mg/day; however, some clinical trials have studied the efficacy of NAC at higher doses. ...Most of the studies used oral NAC and were conducted on patients wit …
N-Acetylcysteine (NAC) is widely used in respiratory medicine, with a maximum licensed dose in chronic use of 600 mg/day; however, so …
Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits.
Pharmacol Ther. 2014 Feb;141(2):150-9. doi: 10.1016/j.pharmthera.2013.09.006. Epub 2013 Sep 28.
Pharmacol Ther. 2014.
PMID: 24080471
Review.
Other therapeutic uses of NAC have also emerged, including the alleviation of clinical symptoms of cystic fibrosis through cysteine-mediated disruption of disulfide cross-bridges in the glycoprotein matrix in mucus. ...
Other therapeutic uses of NAC have also emerged, including the alleviation of clinical symptoms of cystic fibrosis through cysteine-m …
Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis.
Thorax. 2022 Dec;77(12):1243-1250. doi: 10.1136/thoraxjnl-2021-217976. Epub 2022 Feb 10.
Thorax. 2022.
PMID: 35145039
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a respiratory disorder with a poor prognosis. ...Only sildenafil probably reduces acute exacerbation and hospitalisations (moderate certainty). Corticosteroids+azathioprine+N-acetylcysteine increased risk of …
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a respiratory disorder with a poor prognosis. ...Only sildenafil probably r …
Oxidative stress-based therapeutics in COPD.
Redox Biol. 2020 Jun;33:101544. doi: 10.1016/j.redox.2020.101544. Epub 2020 Apr 20.
Redox Biol. 2020.
PMID: 32336666
Free PMC article.
Review.
Oxidative stress amplifies chronic inflammation, stimulates fibrosis and emphysema, causes corticosteroid resistance, accelerates lung aging, causes DNA damage and stimulates formation of autoantibodies. ...Most clinical studies in COPD have been conducted using glutathion …
Oxidative stress amplifies chronic inflammation, stimulates fibrosis and emphysema, causes corticosteroid resistance, accelerates lun …
Effect of Local N-acetyl-cysteine in the Prevention of Epidural Fibrosis in Rat Laminectomy Model.
Asian J Neurosurg. 2018 Jul-Sep;13(3):664-668. doi: 10.4103/ajns.AJNS_294_16.
Asian J Neurosurg. 2018.
PMID: 30283523
Free PMC article.
BACKGROUND: Epidural fibrosis is a major contributing factor to the onset of failed back syndrome. Many studies have attempted to prevent this physiological response. Interestingly, N-acetyl-cysteine (NAC) has been effective in some cases in the treatm …
BACKGROUND: Epidural fibrosis is a major contributing factor to the onset of failed back syndrome. Many studies have attempted to pre …
N-Acetylcysteine.
2024 Feb 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.
2024 Feb 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.
PMID: 30725868
Free Books & Documents.
N-acetylcysteine (NAC) is the mainstay of therapy for acetaminophen toxicity. ...NAC is also approved for use in conditions with abnormal viscid or inspissated mucous secretions, such as pneumonia, bronchitis, tracheobronchitis, cystic fibrosis, tracheostomy patient …
N-acetylcysteine (NAC) is the mainstay of therapy for acetaminophen toxicity. ...NAC is also approved for use in conditions with abno …
N-Acetylcysteine attenuated pulmonary fibrosis induced by bleomycin via immunomodulation responses.
Res Pharm Sci. 2023 Jan 19;18(2):177-184. doi: 10.4103/1735-5362.367796. eCollection 2023 Apr.
Res Pharm Sci. 2023.
PMID: 36873280
Free PMC article.
BACKGROUND AND PURPOSE: Pulmonary fibrosis (PF) is a chronic and life-threatening interstitial lung disease. N-acetyl cysteine (NAC) is an antioxidant pharmaceutically available to reduce endothelial dysfunction, inflammation, and fibrosis …
BACKGROUND AND PURPOSE: Pulmonary fibrosis (PF) is a chronic and life-threatening interstitial lung disease. N-acety …
Efficacy of N-Acetylcysteine in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Medicine (Baltimore). 2016 May;95(19):e3629. doi: 10.1097/MD.0000000000003629.
Medicine (Baltimore). 2016.
PMID: 27175674
Free PMC article.
Review.
There are a number of conflicting reports describing the clinical outcomes of using N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis. We have, therefore, performed a meta-analysis to evaluate the efficacy of N-acetylcysteine, compare …
There are a number of conflicting reports describing the clinical outcomes of using N-acetylcysteine for the treatment of idiopathic …
Idiopathic pulmonary fibrosis: prime time for a precision-based approach to treatment with N-acetylcysteine.
Eur Respir J. 2021 Jan 5;57(1):2003551. doi: 10.1183/13993003.03551-2020. Print 2021 Jan.
Eur Respir J. 2021.
PMID: 33402374
Free article.
No abstract available.
Cite